Compare · GILD vs PTHS
GILD vs PTHS
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Pelthos Therapeutics Inc. (PTHS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and PTHS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $181.46B, about 1968.3x PTHS ($92.2M).
- Over the past year, GILD is up 32.1% and PTHS is up 11.2% - GILD leads by 20.9 points.
- GILD has been more active in the news (10 items in the past 4 weeks vs 7 for PTHS).
- GILD has more recent analyst coverage (25 ratings vs 6 for PTHS).
- Company
- Gilead Sciences Inc.
- Pelthos Therapeutics Inc.
- Price
- $148.94+1.78%
- $25.04+2.37%
- Market cap
- $181.46B
- $92.2M
- 1M return
- +13.52%
- -12.75%
- 1Y return
- +32.13%
- +11.24%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 1992
- 2024
- News (4w)
- 10
- 7
- Recent ratings
- 25
- 6
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- Director Welters Anthony exercised 18,000 shares at a strike of $61.06 and sold $2,675,220 worth of shares (18,000 units at $148.62) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form N-PX filed by Gilead Sciences Inc.
- Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
Latest PTHS
- SEC Form DEFA14A filed by Pelthos Therapeutics Inc.
- SEC Form DEF 14A filed by Pelthos Therapeutics Inc.
- SEC Form 10-Q filed by Pelthos Therapeutics Inc.
- Pelthos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits
- Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
- Amendment: SEC Form 10-Q/A filed by Pelthos Therapeutics Inc.
- Pelthos Therapeutics Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
- SEC Form PRE 14A filed by Pelthos Therapeutics Inc.
- Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
- Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders